Unadapted Epstein-Barr virus-specific T-cell IFNγ production under treatment. Patients with inappropriate Epstein-Barr virus (EBV)-specific T-cell IFNγ production in response to high EBV viral load under treatment. (a) Spondylarthropathy patient with infliximab + methotrexate. (b) Rheumatoid arthritis patient with adalimumab + methotrexate. Both responses to latent peptides and lytic peptides are represented. PBMCs, peripheral blood mononuclear cells; W0, week 0; W12, week 12.